NASDAQ:CNST - Constellation Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.29
  • Forecasted Upside: 109.85 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$21.58
▼ -0.71 (-3.19%)
1 month | 3 months | 12 months
Get New Constellation Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNST

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.29
▲ +109.85% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Constellation Pharmaceuticals in the last 3 months. The average price target is $45.29, with a high forecast of $75.00 and a low forecast of $20.00. The average price target represents a 109.85% upside from the last price of $21.58.
Buy
The current consensus among 7 polled investment analysts is to buy stock in Constellation Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/7/2021Royal Bank of CanadaReiterated RatingBuy$50.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
1/25/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$27.00 ➝ $50.00Low
i
9/24/2020OppenheimerReiterated RatingHold$20.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/8/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/3/2020Brookline Capital ManagementInitiated CoverageBuy$33.00Low
i
Rating by L. Cann at Brookline Capital Management
8/9/2020Jefferies Financial GroupReiterated RatingBuyLow
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/6/2020BMO Capital MarketsLower Price TargetMarket Perform$34.00 ➝ $28.00Medium
i
8/6/2020OppenheimerLower Price TargetOutperform$55.00 ➝ $47.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/6/2020HC WainwrightReiterated RatingBuyMedium
i
7/20/2020Jefferies Financial GroupLower Price TargetBuy$63.00 ➝ $53.00Low
i
6/24/2020JMP SecuritiesInitiated CoverageMarket Perform$36.00Low
i
6/15/2020BMO Capital MarketsLower Price TargetMarket Perform$42.00 ➝ $34.00High
i
Rating by Do Kim at BMO Capital Markets
6/8/2020OppenheimerReiterated RatingBuy$55.00High
i
Rating by Silvan Tuerkcan at Oppenheimer Holdings Inc.
5/7/2020HC WainwrightReiterated RatingBuy$50.00 ➝ $75.00High
i
Rating by Andrew Fein at HC Wainwright
5/6/2020OppenheimerInitiated CoverageBuy$55.00High
i
Rating by Silvan Tuerkcan at Oppenheimer Holdings Inc.
3/11/2020Robert W. BairdLower Price TargetOutperform$65.00 ➝ $55.00High
i
3/11/2020BMO Capital MarketsLower Price TargetIn-Line ➝ Market Perform$42.00 ➝ $35.00Low
i
Rating by Do Kim at BMO Capital Markets
3/11/2020CowenReiterated RatingBuyLow
i
2/13/2020SunTrust BanksInitiated CoverageBuy$50.00High
i
2/7/2020CowenInitiated CoverageOutperformHigh
i
1/9/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$43.00 ➝ $42.00High
i
12/10/2019OppenheimerBoost Price TargetOutperform$40.00 ➝ $55.00Low
i
12/10/2019HC WainwrightReiterated RatingBuy$50.00Low
i
12/10/2019Robert W. BairdReiterated RatingOutperform$35.00 ➝ $65.00High
i
11/7/2019Jefferies Financial GroupReiterated RatingIn-Line ➝ Buy$17.00 ➝ $40.00Medium
i
11/7/2019Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$42.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
11/7/2019HC WainwrightBoost Price TargetBuy$18.00 ➝ $50.00High
i
Rating by Andrew Fein at HC Wainwright
11/6/2019OppenheimerBoost Price Target$18.00 ➝ $40.00High
i
9/4/2019Royal Bank of CanadaInitiated CoverageOutperform$20.00High
i
6/5/2019HC WainwrightReiterated RatingBuy$18.00Low
i
Rating by A. Fein at HC Wainwright
4/2/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$14.00 ➝ $18.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
1/28/2019Robert W. BairdInitiated CoverageOutperform$17.00Medium
i
1/4/2019HC WainwrightReiterated RatingBuy$18.00High
i
Rating by A. Fein at HC Wainwright
12/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
i
Rating by A. Fein at HC Wainwright
11/1/2018OppenheimerSet Price TargetBuy$21.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
8/13/2018OppenheimerInitiated CoverageOutperform$21.00Low
i
8/13/2018JPMorgan Chase & Co.Initiated CoverageOverweight$17.00Low
i
8/13/2018BMO Capital MarketsInitiated CoverageOutperform$19.00Low
i
(Data available from 4/19/2016 forward)
Constellation Pharmaceuticals logo
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $21.58
$21.34
$22.57

50 Day Range

MA: $25.52
$21.84
$30.65

52 Week Range

Now: $21.58
$17.00
$50.90

Volume

19,215 shs

Average Volume

463,718 shs

Market Capitalization

$1.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Constellation Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Constellation Pharmaceuticals in the last year: BMO Capital Markets, Brookline Capital Management, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for CNST.

What is the current price target for Constellation Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Constellation Pharmaceuticals in the last year. Their average twelve-month price target is $45.29, suggesting a possible upside of 109.9%. HC Wainwright has the highest price target set, predicting CNST will reach $75.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $20.00 for Constellation Pharmaceuticals in the next year.
View the latest price targets for CNST.

What is the current consensus analyst rating for Constellation Pharmaceuticals?

Constellation Pharmaceuticals currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNST will outperform the market and that investors should add to their positions of Constellation Pharmaceuticals.
View the latest ratings for CNST.

What other companies compete with Constellation Pharmaceuticals?

How do I contact Constellation Pharmaceuticals' investor relations team?

Constellation Pharmaceuticals' physical mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company's listed phone number is 617-714-0555 and its investor relations email address is [email protected] The official website for Constellation Pharmaceuticals is www.constellationpharma.com.